Preclinical assessment of dual CYP26[A1/B1] inhibitor, DX308, as an improved treatment for keratinization disorders
Abstract Background Retinoid‐based therapies are commonly used in the treatment of disorders of keratinization and other skin disorders but can result in non‐specific effects and adverse reactions. Use of retinoic acid metabolism blocking agents (RAMBAs) such as DX308 may address these shortcomings....
Saved in:
Main Authors: | J.G.S. Veit (Author), Y. Poumay (Author), D. Mendes (Author), J. Kreitinger (Author), L. Walker (Author), A. Paquet (Author), C. Menigot (Author), F. Zolezzi (Author), A.S. Paller (Author), P. Diaz (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2021-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The KEAP1/NRF2 Signaling Pathway in Keratinization
by: Yosuke Ishitsuka, et al.
Published: (2020) -
Keratin
Published: (2018) -
Is the Association Between TNF-α-308 A Allele and DMT1 Independent of HLA-DRB1, DQB1 Alleles?
by: Grazyna Deja, et al.
Published: (2006) -
Two Beats One: Osteosarcoma Therapy with Light-Activated and Chemo-Releasing Keratin Nanoformulation in a Preclinical Mouse Model
by: Elisa Martella, et al.
Published: (2022) -
The Use of CBD and Its Synthetic Analog HU308 in HIV-1-Infected Myeloid Cells
by: Anastasia Williams, et al.
Published: (2023)